- Roche ends work on tominersen after decade of trials, as well as early-stage Huntington’s assetAfter more than a decade of work and plenty of ups and downs, Roche has dropped its Huntington’s disease drug tominersen. The decision comes after tominersen did no better than placebo in a Phase…Endpoints · 15d ago↗ source
- UK price watchdog recommends against Amgen's Lumakras in lung cancerThe UK’s drug pricing watchdog said government reimbursement of Amgen’s lung cancer drug Lumakras should be cut off for new patients. In draft guidance released on Thursday, the National Institut…Endpoints · 15d ago↗ source
- FDA criticizes Lundbeck for webpages on migraine treatment VyeptiThe FDA has chastised Lundbeck Seattle Biopharmaceuticals for two promotional webpages that made allegedly inflated claims regarding the efficacy of its migraine drug. In an untitled letter sent…